Golpimec (Fingolimod)

Golpimec is indicated for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease.

• Reduces the frequency of clinical relapses.
• Slows accumulation of disability as measured by the Expanded Disability Status Scale.
• May decrease the number of new or enlarging MRI lesions.
• Used as a disease‑modifying therapy to alter the underlying disease process.
• Administered as part of a comprehensive management plan that includes monitoring and supportive care.

The safety profile of Golpimec includes a range of observed adverse events, which are generally categorized by frequency and severity.

Common

• Headache
• Diarrhea
• Upper respiratory tract infection
• Elevated liver enzymes
• Decreased lymphocyte count

Serious

• Cardiac conduction abnormalities (e.g., bradycardia)
• Severe infections
• Macular edema
• Respiratory complications
• Liver injury

Before prescribing Golpimec, clinicians should evaluate several precautionary factors to mitigate risks associated with its immunomodulatory action.

• Baseline cardiac assessment, including ECG, due to potential bradyarrhythmia.
• Screening for active infections, especially hepatitis B and tuberculosis.
• Evaluation of liver function tests prior to initiation and during treatment.
• Consideration of vaccination status; live vaccines are contraindicated during therapy.
• Monitoring of lymphocyte counts regularly throughout therapy.
• Assessment of pulmonary function in patients with a history of respiratory disease.
• Caution in women of childbearing potential; discuss contraception and pregnancy planning.

Golpimec can interact with other medicines, influencing its efficacy or safety; known interactions are grouped by recommended management.

Avoid

• Concomitant use with strong CYP4F2 inhibitors, which may increase fingolimod exposure.
• Live attenuated vaccines, as immunosuppression can reduce vaccine effectiveness.

Use with caution

• Beta‑blockers or calcium channel blockers that may exacerbate bradycardia.
• Antiplatelet or anticoagulant agents, due to potential increased bleeding risk.
• Other disease‑modifying therapies for multiple sclerosis, which may compound immunosuppression.
• Vaccines requiring an immune response (e.g., inactivated vaccines) may have reduced efficacy.